MedTech companies’ commitments to broadly defined, clinically oriented missions are becoming less likely to hit financial success.
This is not to say that innovation is out. In fact, some companies continue to generate strong profits from breakthrough products, even in the face of financial concerns, such as earnings levels that lag R&D spending. However, change is afoot
Accenture’s High Performance Business research reveals who the medical technology high performers are, and the trends and recommendations needed to repair the disconnect in this evolving industry.
For the past several years, Accenture has applied the HPB framework to the medical technology industry to help understand what companies are performing well and why. In 2011, we published the full report, "Achieving High Performance: Reinventing Medical Technology for a Dramatically Different Future."
In 2014, we again applied the Accenture HPB framework to the medical technology industry and included 19 “pure play” global MedTech competitors in the analysis. We also added another 11 companies as an extended peer set of diversified companies. Our analysis spanned 2005-2013, and the results provide deep insight into the industry’s performance and its challenges.